Omid Hamid
Cedars-Sinai Medical Center · 901 works · 85,078 citations · h-index 97
Top works
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- An immune-active tumor microenvironment favors clinical response to ipilimumab
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain